Table 3.

Characteristics of patients for transcriptome study

Patient	Gender	Age, years	Sokal score	TKI first line, dosage	Response to TKI
1	Male	36	Intermediate risk	Imatinib, 400 mg	Optimal response
2	Female	27	High risk	Imatinib, 600 mg	Optimal response
3	Female	57	Low risk	Imatinib, 400 mg	Optimal response
4	Female	55	Low risk	Imatinib, 400 mg	Optimal response
5	Female	68	Intermediate risk	Imatinib, 400 mg	Non-optimal response
6	Male	77	Low risk	Imatinib, 400 mg	Optimal response
7	Male	34	Intermediate risk	Imatinib, 400 mg	Non-optimal response
8	Male	20	Low risk	Nilotinib, 600 mg	Optimal response
9	Female	30	Low risk	Imatinib, 400 mg	Non-optimal response
10	Male	30	High risk	Nilotinib, 800 mg	Non-optimal response
11	Female	63	Intermediate risk	Imatinib, 400 mg	Non-optimal response
12	Female	38	Low risk	Imatinib, 400 mg	Optimal response

TKI tyrosine kinase inhibitor